Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Italian expanded access program of Berotralstat for the Prevention of Hereditary Angioedema Attacks

Trial Profile

Italian expanded access program of Berotralstat for the Prevention of Hereditary Angioedema Attacks

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 04 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Berotralstat (Primary)
  • Indications Hereditary angioedema
  • Focus Expanded access; Therapeutic Use

Most Recent Events

  • 04 Jun 2025 New trial record
  • 30 May 2025 According to a BioCryst Pharmaceuticals media release, company to present result data from this study at the 14th C1-Inhibitor Deficiency & Angioedema Workshop in Budapest, Hungary from May 29-June 1, 2025.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top